Clinical Trials Logo

Clinical Trial Summary

This is a multi-center, randomized, open-label pivotal phase II study to evaluate the efficacy and safety of EAL as adjuvant therapy in preventing recurrence in patients with primary HCC at high recurrence risk after radical resection.


Clinical Trial Description

HCC, accounting for 80% of all liver cancers, is the third most common cause of cancer-related death worldwide. Radical resection is considered as a curative strategy for patients with primary HCC. However, over 50% of patients experience recurrence after resection, resulting in a very low 5-year survival rate. EAL are ex vivo expanded and activated lymphocytes comprising mainly CD8+ T cells derived from patients' peripheral blood. This is a multi-center, randomized, open-label pivotal phase II study to evaluate the efficacy and safety of EAL in preventing recurrence in patients with primary HCC at high recurrence risk after radical resection. Patients will be randomized in a 1:1 ratio to receive either 20 doses of EAL (1×10^9~2×10^10 per dose) infusion in combination of a single TACE or a single TACE only. Primary endpoint is the independent review committee-determined recurrence-free survival (from randomization to first recurrence or death from any cause). Secondary endpoints include overall survival, cancer-specific survival, adverse events and others. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05213637
Study type Interventional
Source Chinese PLA General Hospital
Contact Shichun Lu, MD, PhD
Phone 86-10-66938209
Email Lsc620213@aliyun.com
Status Recruiting
Phase Phase 2
Start date April 25, 2018
Completion date April 30, 2023

See also
  Status Clinical Trial Phase
Completed NCT03007212 - Outcome of Transarterial Chemo-embolization (TACE) in Hepatocellular Carcinoma Patients With Partial Portal Vein Thrombosis Phase 4
Terminated NCT03236649 - The Phase III Study of Icaritin Versus Sorafenib in PD-L1 Positive Advanced Hepatocellular Carcinoma Subjects Phase 3
Withdrawn NCT04044326 - The Safety and Efficacy of Spherical Microwave Ablation for the Treatment of Malignant Liver Tumors N/A
Recruiting NCT04687969 - Multimodal Machine Learning Characterization of Solid Tumors
Completed NCT02562755 - Hepatocellular Carcinoma Study Comparing Vaccinia Virus Based Immunotherapy Plus Sorafenib vs Sorafenib Alone Phase 3
Withdrawn NCT02406508 - Sequential Melphalan for Use With Hepatic Delivery System Treatment Followed by Sorafenib in Patients With Unresectable HCC Phase 2
Completed NCT01972672 - The Phase II Study of Icaritin in Patients With Advanced Hepatocellular Carcinoma Phase 2
Completed NCT01247298 - A Pilot Study of Trans Arterial Chemoembolization (TACE), Followed by Stereotactic Radiation Therapy (SBRT) for Patients With Hepatocellular Carcinoma Phase 0
Completed NCT03735628 - An Study to Evaluate the Safety and Efficacy of Copanlisib in Combination With Nivolumab in Patients With Advanced Solid Tumors Phase 1
Completed NCT02188901 - Contrast (Sonazoid)-Enhanced US as a Screening Tool for Hepatocellular Carcinoma in Cirrhosis: An Exploratory Cross-sectional Study N/A
Active, not recruiting NCT04522908 - Dose Escalation Study of Cabozantinib for Advanced HCC Patients With Preserved Liver Function Phase 2
Terminated NCT01433016 - Detection of Hepatocellular Carcinoma (HCC) With Octanoate Breath ID Test Compared to MRI Phase 2
Withdrawn NCT04465734 - A Clinical Study to Compare the Efficacy and Safety of HLX10 in Combination With HLX04 Versus Sorafenib as the First-line Treatment in Patients With Locally Advanced or Metastatic HCC Phase 3
Recruiting NCT05057013 - HMBD-001 in Advanced HER3 Positive Solid Tumours Phase 1/Phase 2
Active, not recruiting NCT03753659 - IMMULAB - Immunotherapy With Pembrolizumab in Combination With Local Ablation in Hepatocellular Carcinoma (HCC) Phase 2
Terminated NCT03144661 - An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies Phase 1
Not yet recruiting NCT01821482 - A Study of DC-CIK to Treat Hepatocellular Carcinoma Phase 2
Completed NCT03516071 - A Phase 2 Study of Brivanib in Chinese Patients With Previously Treated Advanced HCC Phase 2
Completed NCT01761266 - A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-line Treatment of Participants With Unresectable Hepatocellular Carcinoma Phase 3
Completed NCT02794805 - Determination of HCC With Octanoate Breath Test vs. MRI Diagnosis Phase 2